COSCIENS Biopharma Inc.
AEZS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.7M
Close$
$3.61
36.9% downside
Current Fair Value
36.9% downsideOvervalued by 36.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.70 Million |
|---|---|
| Enterprise Value | $9.38 Million |
| Earnings per Share | $-3.65 |
| Beta | 2.26 |
| Outstanding Shares | 2,220,303 |
Return
| Return on Equity | -32.16% |
|---|---|
| Return on Assets | -25.32% |
| Return on Invested Capital | -27.13% |
Valuation & Multiples
| P/E Ratio | -0.46 |
|---|---|
| PEG | 0.5 |
| Price to Sales | 1.91 |
| Price to Book Ratio | 0.95 |
| Enterprise Value to Revenue | 1.13 |
| Enterprise Value to EBIT | -2.09 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Aeterna Zentaris Inc.
28 employees
CEO: Klaus Paulini
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved ora...